NYSE American - Nasdaq Real Time Price USD

Cryo-Cell International, Inc. (CCEL)

4.9009
-0.1091
(-2.18%)
As of 10:42:23 AM EDT. Market Open.
Loading Chart for CCEL
  • Previous Close 5.0100
  • Open 4.9500
  • Bid 4.9000 x 1400
  • Ask 4.9500 x 900
  • Day's Range 4.9009 - 4.9499
  • 52 Week Range 4.7500 - 9.4900
  • Volume 6,900
  • Avg. Volume 13,072
  • Market Cap (intraday) 39.61M
  • Beta (5Y Monthly) 0.81
  • PE Ratio (TTM) 490.09
  • EPS (TTM) 0.0100
  • Earnings Date Jul 14, 2025 - Jul 18, 2025
  • Forward Dividend & Yield 0.60 (11.98%)
  • Ex-Dividend Date May 21, 2025
  • 1y Target Est 8.50

Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

www.cryo-cell.com

82

Full Time Employees

November 30

Fiscal Year Ends

Recent News: CCEL

View More

Performance Overview: CCEL

Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CCEL
31.70%
S&P 500 (^GSPC)
0.98%

1-Year Return

CCEL
42.11%
S&P 500 (^GSPC)
12.00%

3-Year Return

CCEL
6.53%
S&P 500 (^GSPC)
52.26%

5-Year Return

CCEL
11.41%
S&P 500 (^GSPC)
103.20%

Compare To: CCEL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CCEL

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    40.49M

  • Enterprise Value

    50.87M

  • Trailing P/E

    397.08

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.26

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    1.58

  • Enterprise Value/EBITDA

    8.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.40%

  • Return on Assets (ttm)

    3.99%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    32.1M

  • Net Income Avi to Common (ttm)

    128.71k

  • Diluted EPS (ttm)

    0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.48M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.07M

Research Analysis: CCEL

View More

Company Insights: CCEL

Research Reports: CCEL

View More

People Also Watch